Prognostic Value of Tricuspid Valve Gradient After Transcatheter Edge-to-Edge Repair: Insights From the TriValve Registry
Augustin Coisne,Andrea Scotti,Maurizio Taramasso,Juan F Granada,Sebastian Ludwig,Josep Rodés-Cabau,Philipp Lurz,Jörg Hausleiter,Neil Fam,Susheel K Kodali,Alberto Pozzoli,Hannes Alessandrini,Luigi Biasco,Eric Brochet,Paolo Denti,Rodrigo Estevez-Loureiro,Christian Frerker,Edwin C Ho,Vanessa Monivas,Georg Nickenig,Fabien Praz,Rishi Puri,Horst Sievert,Gilbert H L Tang,Martin Andreas,Ralph Stephan Von Bardeleben,Karl-Philipp Rommel,Guillem Muntané-Carol,Mara Gavazzoni,Daniel Braun,Edith Lubos,Daniel Kalbacher,Kim A Connelly,Jean-Michel Juliard,Claudia Harr,Giovanni Pedrazzini,François Philippon,Joachim Schofer,Holger Thiele,Matthias Unterhuber,Dominique Himbert,Marina Ureña Alcázar,Mirjam G Wild,Ulrich Jorde,Stephan Windecker,Francesco Maisano,Martin B Leon,Rebecca T Hahn,Azeem Latib
DOI: https://doi.org/10.1016/j.jcin.2023.01.375
2023-03-10
Abstract:Background: Data regarding the impact of the tricuspid valve gradient (TVG) after tricuspid transcatheter edge-to-edge repair (TEER) are scarce. Objectives: This study sought to evaluate the association between the mean TVG and clinical outcomes among patients who underwent tricuspid TEER for significant tricuspid regurgitation. Methods: Patients with significant tricuspid regurgitation who underwent tricuspid TEER within the TriValve (International Multisite Transcatheter Tricuspid Valve Therapies) registry were divided into quartiles based on the mean TVG at discharge. The primary endpoint was the composite of all-cause mortality and heart failure hospitalization. Outcomes were assessed up to the 1-year follow-up. Results: A total of 308 patients were included from 24 centers. Patients were divided into quartiles of the mean TVG as follows: quartile 1 (n = 77), 0.9 ± 0.3 mm Hg; quartile 2 (n = 115), 1.8 ± 0.3 mm Hg; quartile 3 (n = 65), 2.8 ± 0.3 mm Hg; and quartile 4 (n = 51), 4.7 ± 2.0 mm Hg. The baseline TVG and the number of implanted clips were associated with a higher post-TEER TVG. There was no significant difference across TVG quartiles in the 1-year composite endpoint (quartiles 1-4: 35%, 30%, 40%, and 34%, respectively; P = 0.60) or the proportion of patients in New York Heart Association class III to IV at the last follow-up (P = 0.63). The results were similar after adjustment for clinical and echocardiographic characteristics (composite endpoint quartile 4 vs quartile 1-quartile 3 adjusted HR: 1.05; 95% CI: 0.52-2.12; P = 0.88) or exploring post-TEER TVG as a continuous variable. Conclusions: In this retrospective analysis of the TriValve registry, an increased discharge TVG was not significantly associated with adverse outcomes after tricuspid TEER. These findings apply for the explored TVG range and up to the 1-year follow-up. Further investigations on higher gradients and longer follow-up are needed to better guide the intraprocedural decision-making process.